Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia
Launched by GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO · Jul 2, 2010
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES:
* To determine the feasibility of combination chemotherapy in young adult patients with acute lymphoid leukemia.
* To determine the complete response rate at the end of induction therapy in these patients.
* To determine the overall survival of patients treated with these regimens.
* To determine the disease-free survival of patients treated with these regimens.
* To determine the event-free survival of patients treated with these regimens.
* To determine toxicity of these regimens.
* To determine compliance related to dose intensity.
OUTLINE:
* Steroids prephase therapy: All...
Gender
ALL
Eligibility criteria
- DISEASE CHARACTERISTICS:
- * Diagnosis of acute lymphoid leukemia, meeting any of the following criteria:
- • Non-mature B-cell disease
- • Non-Philadelphia chromosome positive disease
- • T -cell or B-cell phenotype
- PATIENT CHARACTERISTICS:
- • Not specified
- PRIOR CONCURRENT THERAPY:
- • Prior pretreatment with antiblastic chemotherapy allowed
About Gruppo Italiano Malattie Ematologiche Dell'adulto
The Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) is a prestigious Italian research group dedicated to advancing the understanding and treatment of adult hematological diseases. Comprising a network of leading hematologists and clinical researchers, GIMEMA conducts innovative clinical trials aimed at improving patient outcomes through the development of novel therapeutic strategies and evidence-based practices. With a strong emphasis on collaboration and scientific rigor, GIMEMA plays a pivotal role in enhancing the landscape of hematology both in Italy and internationally, contributing significantly to the global body of research and clinical knowledge in this critical field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, , Italy
Udine, , Italy
Ancona, , Italy
Avellino, , Italy
Bologna, , Italy
Brindisi, , Italy
Catania, , Italy
Milano, , Italy
Palermo, , Italy
Pescara, , Italy
Roma, , Italy
Roma, , Italy
Roma, , Italy
Roma, , Italy
Verona, , Italy
Genova, , Italy
Napoli, , Italy
Reggio Calabria, , Italy
Sassari, , Italy
Ascoli Piceno, , Italy
Nocera Inferiore, , Italy
Lecce, , Italy
Novara, , Italy
San Giovanni Rotondo, , Italy
Arezzo, , Italy
Catanzaro, , Italy
Modena, , Italy
Parma, , Italy
Roma, , Italy
Ferrara, , Italy
Palermo, , Italy
Roma, , Italy
Bari, , Italy
Ravenna, , Italy
Reggio Emilia, , Italy
Messina, , Italy
Pavia, , Italy
Roma, (Rm), Italy
Napoli, , Italy
Napoli, , Italy
Pisa, , Italy
Roma, , Italy
Trani, , Italy
Patients applied
Trial Officials
Roberto Foa, MD
Principal Investigator
Universita Degli Studi "La Sapeinza"
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials